AGC Biologics and Evax Partner to Advance Promising Equine Allergy Vaccine Candidate
The CDMO supports clinical stages using its Heidelberg site’s microbial-based biologics services
Seattle, Sept. 07, 2022 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with Evax, a developer of equine vaccines to treat chronic diseases, respiratory disorders and allergies. Through this partnership, Evax advances its Antigen VLP Conjugate product into the clinical stage, and AGC Biologics will supply cGMP support for the pivotal studies.
AGC Biologics is providing services at its Heidelberg facility using microbial-based protein biologics systems. The project covers Process Development and Clinical Manufacturing for the Evax Antigen-VLP Conjugate product.
The Evax drug candidate is focused on treating summer eczema, also called sweet itch or insect bite hypersensitivity (IBH), which is one of the most prevalent allergic skin diseases in horses. It manifests as chronic relapsing seasonal allergic dermatitis (inflammatory reaction of the skin).
“For many equine diseases only limited therapeutic treatment options are available with sometimes poor efficacy,” said Dr. Antonia Gabriel, CEO and Founder of Evax. “We believe in this product and are ready to display its abilities in the clinical stages. Further, AGC Biologics and the capabilities at its Heidelberg site are an ideal fit to help guide us through this important phase of the journey.”
AGC Biologics’ Heidelberg facility has more than 20 years of experience delivering a wide range of microbial programs for developers at various stages. To date, it has supported over 100 different microbial processes for different projects, and produced two commercial products. In addition, the site is the CDMO’s Center of Excellence for Plasmid DNA (pDNA) and messenger RNA (mRNA) production, playing a vital role in the company’s global Cell and Gene Therapy services offering.
“The specialized work that Evax is performing for the equine market is truly unique and we are happy to be supporting this important program,” said JB Agnus, Chief Business Officer of AGC Biologics. “This partnership shows the true depth of our services. Thanks to our strong global network, we feel we can support any clinical and commercial projects with reliable, innovative and cost competitive solutions.”
AGC Biologics’ microbial services use various technologies and scales, and the CDMO has successfully expressed antibody fragments, growth factors, antigens, enzymes, virus-like-particles (VLPs), and other proteins. The company has experience with E. coli and Pichia microbial expression platforms, and it uses multiple modes of expression—including secretion (yeast), periplasmic secretion, soluble intracellular expression, and inclusion bodies.
To learn more about the company and its biologics and cell and gene services, visit www.agcbio.com.
About EVAX
EVAX develops new equine vaccines to treat chronic diseases, allergies, and respiratory disorders. For many equine diseases only limited therapeutic treatment options are available with sometimes poor efficacy. Hence, there is a major need for new, innovative, specific and efficacious equine therapeutics. Our mission is to transfer human standards of care into horses at an affordable price. The company is committed to the development of Equine Vaccines and Innovative Healthcare for Horses. To learn more visit https://www.evax.ch/en/.
About AGC Biologics
AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and we currently employ more than 2,500 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. To learn more, visit www.agcbio.com.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Notice on Convocation of Extraordinary General Meeting of Shareholders of AB Klaipėdos nafta30.9.2022 08:00:00 CEST | Press release
Notice is hereby given that on the initiative and by the resolution of the Board of AB Klaipėdos nafta, legal entity code 110648893, with the registered office at Burių str. 19, Klaipeda (hereinafter - the Company), Exraordinary General Meeting of Shareholders of the Company will be held on 20 October 2022 at 1:00 p.m. The meeting will be held in the Company’s office at Buriu str. 19, Klaipeda, in the administrative office of the Company (in the hall of the meeting on the 2nd floor). Agenda of the meeting: Approval of amendment of Remuneration Policy of AB Klaipėdos nafta. The shareholders will be registered from 12:00 a.m. to 12:55 p.m. The persons intending to participate in the meeting shall have a personal ID document (an authorized representative shall have an authorization approved under the established procedure. The natural person’s authorization shall be notarized. An authorization issued in a foreign state shall be translated into the Lithuanian language and legalized under t
Kitron: Ferroamp signs production agreement with Kitron30.9.2022 08:00:00 CEST | Press release
(2022-09-30) Kitron has entered into a production agreement with Ferroamp, a rapidly growing Swedish greentech company. The value of the agreement is expected to reach approximately NOK 90 million in 2023 and NOK 350 million over a three-year period. Ferroamp has developed EnergyHub, a system that controls electricity use using a patented DC technology, so that property owners can get more out of their solar panels and integrate electric car charging and energy storage. During the first half of 2022, Ferroamp increased its sales by 60 percent and is now planning an international launch. “Ferroamp continues to expand its operations through collaborations with strategic partners. We are delighted to have signed an agreement with Kitron, which has a leading position in electronics production and has the capacity to produce large volumes of EnergyHub systems for our residential customers,” says Krister Werner, CEO of Ferroamp. The EnergyHub system is available for both commercial propertie
Kitron: Ferroamp inngår produksjonsavtale med Kitron30.9.2022 08:00:00 CEST | Pressemelding
(2022-09-30) Kitron har inngått en produksjonsavtale med Ferroamp, et raskt voksende svensk miljøteknologiselskap. Verdien av avtalen forventes å være rundt 90 millioner kroner i 2023 og 350 millioner kroner over en treårsperiode. Ferroamp har utviklet EnergyHub, et system som styrer strømforbruk ved hjelp av patentert DC-teknologi slik at eiendomsbesittere kan utnytte solcellepanelene sine bedre samt integrere elbillading og energilagring. I løpet av første halvår 2022 økte Ferroamp salget med 60 prosent og planlegger nå en internasjonal lansering. – Ferroamp fortsetter å utvide sin virksomhet gjennom samarbeid med strategiske partnere. Vi er glade for å ha inngått en avtale med Kitron, som har en ledende posisjon innen elektronikkproduksjon og kapasitet til å produsere store volumer EnergyHub-systemer for våre kunder i boligmarkedet, sier Krister Werner, administrerende direktør i Ferroamp. EnergyHub-systemet er tilgjengelig for både næringseiendommer og flerfamiliebygg, og EnergyHub
Equinor utnevner Torgrim Reitan til ny finansdirektør30.9.2022 08:00:00 CEST | Pressemelding
Torgrim Reitan er utnevnt til ny konserndirektør for finans i Equinor (OSE: EQNR, NYSE: EQNR), med virkning fra 6. oktober 2022. Reitan etterfølger Ulrica Fearn som har besluttet å slutte i selskapet for å bli finansdirektør i et selskap utenfor Equinor. Ulrica Fearn vil være tilgjengelig for å sikre en god overlevering til Reitan inntil videre. – Jeg er veldig glad for å ønske Torgrim tilbake konsernledelsen. Torgrim har en veldig solid bakgrunn for å ta ansvaret som finansdirektør i Equinor, og for å være en drivkraft i arbeidet med å nå vår ambisjon om å være et ledende selskap i det grønne skiftet. I dagens energikrise er det en styrke å ha Torgrim I toppledelsen, med hans erfaring brede erfaring som finansdirektør, fra vår oppstrømsvirksomhet, fra forretningsområdet for trading og drift av naturgass, og sist fra arbeidet med å akselerere veksten i vår fornybarvirksomhet, sier Anders Opedal, konsernsjef i Equinor. – Jeg ser frem til å bli en del av konsernledelsen, og til å jobbe t
Equinor appoints Torgrim Reitan as new Chief Financial Officer30.9.2022 08:00:00 CEST | Press release
Torgrim Reitan has been appointed Chief Financial Officer and executive vice president in Equinor (OSE: EQNR, NYSE: EQNR), with effect from 6 October 2022. Reitan succeeds Ulrica Fearn who has decided to leave the company to pursue a CFO opportunity outside the company. Ulrica Fearn will be available to secure a good hand over to her successor until further notice. “I am very pleased to welcome Torgrim back to the Corporate Executive Committee. Torgrim has a very strong background to take on the complex challenge as CFO in Equinor, as we progress our ambition to be a leading company in the energy transition. In the current energy crisis, it is a definite strength to have Torgrim in my top management team, with his experience as CFO, from our upstream business, from trading and operations of natural gas, and lastly from the acceleration of growth in our renewables business,” says Anders Opedal, president and CEO of Equinor. “I look very much forward to joining the CEC and to work closel